Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

• Status: Not yet recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to observe the clinical effect and safety of Recombinant Human Endostatin in non-small cell lung cancer with leptomeningeal metastasis

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hui Bu
• Treatments: Endostatins; Methotrexate

Criteria

Inclusion Criteria:

1. Age over 18 years old

2. Pathologically proven non-small cell lung cancer

3. Karnofsky performance status ≥ 40

4. LM diagnosis was based on the detection of malignant cells in the CSF, the focal or diffuse enhancement of leptomeninges, and nerve roots or the ependymal surface on gadolinium-enhanced MRI .

5. No severe abnormal liver and kidney function;

6. Patients have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Evidence of bleeding diathesis or serious infection

2. Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia, unstable angina, myocardial infarction, serious heart valve disease, resistant hypertension)

3. Pregnant or lactating women